Literature DB >> 29922468

First report of Comamonas kerstersii causing urinary tract infection.

M Almuzara1, R Cittadini2, M L Estraviz2, A Ellis2, C Vay1,2.   

Abstract

The association of Comamonas kerstersii with peritonitis resulting from perforated appendix and its isolation from a psoas abscess and pelvic peritonitis have previously been described by us. We present the first case of C. kerstersii urinary tract infection, broadening the spectrum of infections caused by this species.

Entities:  

Keywords:  Comamonas kerstersii; emerging pathogen; psoas abscess; secondary peritonitis; urinary tract infection

Year:  2018        PMID: 29922468      PMCID: PMC6004729          DOI: 10.1016/j.nmni.2018.03.003

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Comamonas spp. are nonfermenting Gram-negative bacilli of the Comamonadaceae family. The genus includes 22 species. Mainly Comamonas testosteroni and Delftia (Comamonas) acidovorans have been implicated in human infections [1]. However, an increase in the number of reports of human infections by another species, Comamonas kerstersii, described in 2003 by Wauters et al. [2], has recently been observed [3], [4]. In this sense, the use of new and revolutionary methodologies for bacterial identification in routine laboratory practice, such as matrix-assisted desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) [5], [6], could explain the increase in the frequency of isolation of this species reported in the literature in recent years [3], [4], [7], [8]. A previously healthy 5-year-old girl with no history of urinary tract infection but with abdominal and low back pain, fever and vomiting was hospitalized to rule out an acute surgical abdomen. The physical examination and the abdominal ultrasound revealed nothing abnormal, but the patient had persistent fever, abdominal pain and positive fist percussion. Therefore, pyelonephritis was diagnosed. A peripheral venous blood sample collected at admission showed white blood cell count 24 900/mm3 (with 83% neutrophils), haematocrit 38%, haemoglobin count 12.4 g/dL, platelet count 286 000/mm3, erythrocyte sedimentation rate 86 mm, blood urea nitrogen level 21 mg/dL and creatinine level 0.5 mg/dL. In addition, a kidney ultrasound revealed both kidneys had preserved shape, size and structure, although an 8.1 mm left pyelocalyceal dilatation was observed. Microscopic analysis of urine revealed 20 leukocytes per high-power field, four erythrocytes per high-power field and two epithelial cells per high-power field. After 24 hours of incubation at 35°C, a pure growth of a nonfermenting Gram-negative bacillus of more than 105 CFU/mL on cystine lactose electrolyte deficient agar, incubated at ambient air temperature, was observed. The patient was treated empirically with ceftriaxone 50 mg/kg per day for 3 days. The microorganism was identified as Comamonas kerstersii by MALDI-TOF MS using a Microflex LT instrument with Biotyper 3.1 software (Bruker Daltonics, Bremen, Germany), with a spectral score of 2.134. Phenotypic identification was confirmed by molecular identification (amplification and subsequent sequencing of the gyrB gene) using the primers described by Tayeb et al. [9]. gyrB gene sequence analysis revealed 99% identity with the gyrB sequence of Comamonas kerstersii (GenBank accession no. KC714047). The minimal inhibitory concentration (μg/mL) using the VITEK 2 System (AST-082 panel; bioMérieux, Marcy l'Étoile, France) was as follows: ampicillin 16; Ampicillin/sulbactam (AMS) ≤ 2; cephalothin ≤ 2; piperacillin-tazobactam ≤ 4; cefotaxime 2; ceftazidime 2; cefepime 8; imipenem ≤ 0.25; meropenem ≤ 0.25; amikacin 16; gentamycin 8; ciprofloxacin ≤ 0.25; Trimethoprim/sulfamethoxazole (TMS) ≤ 2; colistin ≤ 0.5. The minimal inhibitory concentration results were interpreted using Clinical and Laboratory Standards Institute categories [10]. With the report of growth of a nonfermenting Gram-negative bacillus, antibiotic therapy was changed to piperacillin/tazobactam 200 mg/kg per day provided intravenously every 8 hours for a 10-day period. The patient had a favourable progress and was therefore discharged, completing a 14-day treatment with oral amoxicillin/clavulanic 50 mg/kg per day. The association of Comamonas kerstersii with peritonitis resulting from the presence of perforated appendix has previously been described by us [7]. Recently, other authors have also reported new cases of intra-abdominal infections due to perforated appendix [3], as well as the first case of bacteraemia by C. kerstersii in a 65-year-old patient with signs of diverticulosis [4]. In addition, we have recently pointed out the isolation of this microorganism, not previously described in the literature, from two forms of unusual infection presentations: psoas abscess and pelvic peritonitis [8]. The increase in C. kerstersii isolation frequency from human infections in the literature points at it as an emerging pathogen (Table 1). These findings suggest that infections caused by C. kerstersii could be underestimated because identification of isolates using only conventional phenotypic methods does not allow accurate determination of the genus. In the pre–MALDI-TOF MS era, the identification of Comamonas isolates was only achieved by phenotypic methods, which do not allow differentiation among species of genus [7].
Table 1

Clinical and microbiologic characteristics of patients with Comamonas kerstersii infections

Case No.Age (years)/SexSite of infectionClinical presentationUnderlying diseasePredisposing conditionsIdentified pathogensAntibiotic treatmentReference
143, FPeritoneal fluidFebrile syndrome, abdominal painOvarian tumour with peritoneal metastasesSigmoid perforation by foreign body (biliary stent), rectovaginal fistula and colostomyEscherichia coli, Bacteroides fragilis, Comamonas kerstersiiAmpicillin/sulbactam followed by piperacillin/tazobactam and then ertapenem[7]
248, MPeritoneal fluidFebrile syndrome, abdominal pain for 3 daysNo underlying diseasePerforated appendixStreptococcus anginosus group, Aeromonas hydrophila group, Escherichia coli, Comamonas kerstersiiAmpicillin/sulbactam, ciprofloxacin and then amoxicillin/clavulanic acid[7]
310, FPeritoneal fluidAbdominal pain for 3 days, bilious vomiting and febrile eventsNo underlying diseasePerforated gangrenous appendixStreptococcus anginosus group, Escherichia coli, Comamonas kerstersiiAmpicillin/metronidazole/gentamicin and then amoxicillin/clavulanic acid[7]
421, FPeritoneal fluidAbdominal pain for 3days associated with vomitingNo underlying diseasePerforated gangrenous appendixCitrobacter amalonaticus, Comamonas kerstersiiAmpicillin/metronidazole/gentamicin[7]
565, MBloodFever, chills, vomiting, diarrheaDiabeticNoneComamonas kerstersii, Bacteroides fragilisCiprofloxacin, imipenem[4]
612, MPeritoneal fluidAbdominal painNoneAppendicitisComamonas kerstersii, Escherichia coli, Streptococcus sp. (group anginosus/milleri)Coamoxicillin, metronidazole and amikacin followed by coamoxicillin alone[4]
710, MPeritoneal fluidAbdominal painNonePerforated appendicitisComamonas kerstersii Streptococcus constellatusPiperacillin/tazobactam and then amoxicillin clavulanic acid and ciprofloxacin[3]
89, MPeritoneal fluidAbdominal pain, pyrexiaNonePerforated appendicitisComamonas kerstersii Streptococcus constellatus, Bacteroides fragilisAmoxicillin/clavulanic acid, gentamicin and metronidazole and then oral amoxicillin/clavulanic acid[3]
954, FPsoas abscessSeptic shock. Diabetic ketoacidosisObesity, hypertension and diabetesLeft psoas abscessComamonas kerstersii, Escherichia coli, Bacteroides fragilisPiperacillin/tazobactam + vancomycin and then trimethoprim/sulfamethoxazole + metronidazole[8]
1015, FPeritoneal fluidAbdominal pain, vomiting, febrile syndromeNo underlying diseasePurulent peritonitis, salpingitisComamonas kerstersii, Escherichia coli, Streptococcus anginosus, Bacteroides fragilisCeftriaxone, metronidazole, doxycycline, oral amoxicillin/clavulanic acid[8]
1136, FPeritoneal fluidAbdominal pain, nausea, vomitingNo underlying diseaseGangrenous appendicitis, purulent peritonitisBacteroides fragilis, Comamonas kerstersiiAmpicillin, ampicillin/sulbactam, piperacillin/tazobactam[8]
1261, MPeritoneal fluidAbdominal pain, febrile syndromeNo underlying diseaseGangrenous acute appendicitis, acute peritonitisEscherichia coli, Comamonas kerstersiiPiperacillin/tazobactam[8]
1340, MPeritoneal fluidAbdominal pain, febrile syndrome, vomitingNo underlying diseaseGangrenous acute appendicitis, acute generalized peritonitisEscherichia coli, Comamonas kerstersiiCeftriaxone, ornidazole[8]
1438, FPeritoneal fluidAbdominal pain, febrile syndromeNo underlying diseaseAcute appendicitis, pelvic abscessEscherichia coli Comamonas kerstersiiCiprofloxacin, metronidazole[8]
1518, FPeritoneal fluidAbdominal pain, fever, nausea, vomitingNo underlying diseaseGangrenous acute appendicitis with perforated base, generalized peritonitisStreptococcus viridans group Comamonas kerstersiiPiperacillin/tazobactam, ampicillin/sulbactam[8]
1621, FPeritoneal fluidAbdominal pain, febrile syndromeNo underlying diseaseGangrenous appendicitis, purulent peritonitisCitrobacter amalonaticus, Comamonas kerstersiiCeftriaxone, ornidazole[8]
1784, MPeritoneal fluidAbdominal pain, febrile syndromeNo underlying diseasePerforated appendicitisEscherichia coli, Comamonas kerstersiiCeftriaxone, ornidazole[8]
1832, MPeritoneal fluidFever, retroperitoneal haematomasmoking, inhalational drugsFirearm wound; colon perforation, faecal peritonitis, interloop abscessesStreptococcus anginosus, Comamonas kerstersiiPiperacillin/tazobactam, vancomycin, colistin + drainage[8]
1919, MPeritoneal fluidAcute abdomenNo underlying diseasePerforated appendicitis, peritonitis appendicularEscherichia coli, Comamonas kerstersiiAmpicillin, gentamicin, metronidazole[8]
2035, MPeritoneal fluidAbdominal painNo underlying diseasePeritonitis appendicularEscherichia coli, Comamonas kerstersiiCiprofloxacin, metronidazole[8]
2167, MPeritoneal fluidAcute abdomenGlioblastoma multiforme, hypertension, mitral valve surgeryPurulent peritonitis resulting from perforated sigmoidEscherichia coli, Streptococcus viridans group, Bacteroides fragilis, Comamonas kerstersiiAmpicillin/sulbactam, amoxicillin/clavulanate after oral + colostomy[8]
2263, MPeritoneal fluidAbdominal painDiabetes, dyslipidaemia, obesityDiverticulum, appendicular purulent peritonitisEscherichia coli, Comamonas kerstersiiCiprofloxacin, metronidazole[8]
235, FUrineAbdominal and low back pain, fever and vomitingNo underlying diseaseNoneComamonas kerstersiiCeftriaxone, then piperacillin/tazobactam followed by oral amoxicillin/clavulanic acid.Present case
Clinical and microbiologic characteristics of patients with Comamonas kerstersii infections The use of mass spectrometry in routine bacterial identification has revolutionized microbiology. The potential for identification at the species level within minutes makes MALDI-TOF MS an ongoing revolution in the clinical microbiology laboratory [5]. MALDI-TOF MS is a powerful tool not only for routine bacterial identification but also for identification of rare bacterial species implicated in human infectious diseases [6]. In this regard, we have recently demonstrated the ability of MALDI-TOF MS to identify 29 genera of nonfermenting Gram-negative bacilli, including uncommon species. Specifically, C. kerstersii isolates (n = 10) included in our study were correctly identified at the species level [11]. In agreement with Opota et al. [4], we consider that the use of this revolutionary methodology could help establish the epidemiology and clinical impact of this species. Here we describe the first case of urinary tract infection due to C. kerstersii. In view of the finding of this unusual pathogen as a potential cause of urinary tract infection, we looked for this microorganism in the patient's faeces, but only a few colonies of C. kerstersii were found in a culture mainly containing Escherichia coli. Comamonas kerstersii growth in pure culture of more than 105 CFU/mL in urine culture, the presence of leukocyturia and the intestinal colonization associated with clear clinical and radiologic signs of pyelonephritis in this patient pointed to C. kerstersii as the aetiologic agent of this infection; the ascending path was the most likely route of infection. Comamonas kerstersii isolation from the stool of patients with gastroenteritis has recently been reported by us [8] and by other authors [3], indicating a potential intestinal carriage resulting from environmental exposure. We highlight the possibility of C. kerstersii isolation from extraintestinal sites. Therefore, the isolation of C. kerstersii from urinary tract infections broadens the spectrum of infections caused by this microorganism.
  9 in total

1.  Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  Piseth Seng; Michel Drancourt; Frédérique Gouriet; Bernard La Scola; Pierre-Edouard Fournier; Jean Marc Rolain; Didier Raoult
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

2.  Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry for species identification of nonfermenting Gram-negative bacilli.

Authors:  Marisa Almuzara; Claudia Barberis; Germán Traglia; Angela Famiglietti; Maria Soledad Ramirez; Carlos Vay
Journal:  J Microbiol Methods       Date:  2015-03-10       Impact factor: 2.363

3.  Identification of rare pathogenic bacteria in a clinical microbiology laboratory: impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Piseth Seng; Cedric Abat; Jean Marc Rolain; Philippe Colson; Jean-Christophe Lagier; Frédérique Gouriet; Pierre Edouard Fournier; Michel Drancourt; Bernard La Scola; Didier Raoult
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

4.  Comamonas kerstersii and the perforated appendix.

Authors:  Jason S Biswas; Joseph Fitchett; Geraldine O'Hara
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

5.  Comparative phylogenies of Burkholderia, Ralstonia, Comamonas, Brevundimonas and related organisms derived from rpoB, gyrB and rrs gene sequences.

Authors:  Lineda Ait Tayeb; Martine Lefevre; Virginie Passet; Laure Diancourt; Sylvain Brisse; Patrick A D Grimont
Journal:  Res Microbiol       Date:  2007-12-24       Impact factor: 3.992

6.  Intra-abdominal infections due to Comamonas kerstersii.

Authors:  Marisa N Almuzara; Rosana Cittadini; Cecilia Vera Ocampo; Romina Bakai; German Traglia; Maria S Ramirez; Marcelo del Castillo; Carlos A Vay
Journal:  J Clin Microbiol       Date:  2013-04-10       Impact factor: 5.948

7.  Bacteremia caused by Comamonas kerstersii in a patient with diverticulosis.

Authors:  Onya Opota; Barbara Ney; Giorgio Zanetti; Katia Jaton; Gilbert Greub; Guy Prod'hom
Journal:  J Clin Microbiol       Date:  2013-12-26       Impact factor: 5.948

8.  Description of Comamonas aquatica comb. nov. and Comamonas kerstersii sp. nov. for two subgroups of Comamonas terrigena and emended description of Comamonas terrigena.

Authors:  Georges Wauters; Thierry De Baere; Anne Willems; Enevold Falsen; Mario Vaneechoutte
Journal:  Int J Syst Evol Microbiol       Date:  2003-05       Impact factor: 2.747

9.  Unusual presentations of Comamonas kerstersii infection.

Authors:  M Almuzara; C Barberis; F Veiga; R Bakai; R Cittadini; C Vera Ocampo; M Alonso Serena; E Cohen; M S Ramirez; A Famiglietti; D Stecher; M Del Castillo; C Vay
Journal:  New Microbes New Infect       Date:  2017-07-12
  9 in total
  2 in total

1.  Comamonas kerstersii Bacteremia of Unknown Origin.

Authors:  Kassie Rong; Johan Delport; Fatimah AlMutawa
Journal:  Case Rep Infect Dis       Date:  2022-03-27

2.  Maternal peripartum bacteremia caused by intrauterine infection with Comamonas kerstersii: A case report.

Authors:  Hai Qu; Yi-Hong Zhao; Wen-Mei Zhu; Lu Liu; Ming Zhu
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.